Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MODERNA RECEIVES FDA AUTHORIZATION FOR EMERGENCY USE OF ITS COVID-19 VACCINE FOR CHILDREN 6 MONTHS OF AGE AND OLDER
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-FDA-Authorization-for-Emergency-Use-of-Its-COVID-19-Vaccine-for-Children-6-Months-of-Age-and-Older/default.aspx
Very nice Bro
MRNA $$$$$
Share Repurchase Program: As announced last quarter, the Board of Directors authorized a share repurchase program for $3 billion in February 2022 to return excess capital to shareholders. The previous program of $1 billion announced in August 2021 has been fully utilized as of the end of January 2022.
is in progress$$$$$$$$$$
imo..@@' smh......mRNA...my...retirementshortune.\...it's sad...c<3pt i'm not in :(.
This is why an Omicron specific vaccine is so important. As you may already know, some viruses are stable and some mutate every 2 weeks or so.
The Omicron variant has so many changes to the spike protein that it evades the body’s immune response generated by both having original COVID and/or vaccination.
Fauci is truthful about his experience and BECAUSE he was vaccinated and boosted, he has mild symptoms.
The ability of Moderna to rapidly scale up production within their proven platform without using chicken eggs of a new vaccine is a game changer
Looking forward for a good 2022 for MRNA $$$$$
The moderna series for toddlers only requires one month versus 3 months for pfizer. Think about return to school. Moderna will be the winner here by far. Two shots versus three for pfizer
US government advisers have recommended administering Covid-19 vaccines to babies and toddlers, paving the way for the nationwide rollout of jabs from as early as next week!
https://www.ft.com/content/9dd04cfb-e262-4242-988f-0f2f9f86b0a3?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
Moderna, Inc. (MRNA) Management Presents at 43rd Annual Goldman Sachs Global Healthcare Conference (Transcript)
Salveen Richter
On your pipeline outside of the infectious disease vertical, you have a personalized cancer vaccine drug with Merck, and we are going to see data in the second half. Maybe frame for us how we should be thinking about this data, because to-date, with cancer vaccines, it’s just been viewed as early proof of concept. So, is this meaningful? What are you looking for? And then what does it mean for that vertical as a whole?
Lavina Talukdar
Yes. Great question. So, you are right. We will be looking for data coming out of our Phase 2 PCV study. So, let me just explain what we are looking for in that data set. So, this is a landmark-type study that is head-to-head against KEYTRUDA as a standalone medicine for patients with adjuvant melanoma. And we are looking to show that the combination of our PCV plus KEYTRUDA shows higher percentage of people who are living recurrence-free from their adjuvant melanoma at the 12-month mark, which is why we can say that it’s – since it’s a timed endpoint, that we will have that data available in the fourth quarter of this year. And so we know that KEYTRUDA, which is already approved in that setting, shows somewhere between 60% and 70% recurrence-free survival rate at the 12-month mark. So, what we will look to do there is increase the percentage of people who are living recurrence-free at 12 mark – at the 12-month mark when they are getting PCV plus KEYTRUDA. So, it’s proof-of-concept because this will be the first instance where we can show the additive value of PCV to KEYTRUDA because it is a head-to-head study. And then once we show that data set, because we know KEYTRUDA works in many other cancers and because, by this data set, we will know if the mechanism of action is complementary, it will beg the question, where else can this mechanism of action, that’s synergistic between PCV as well as KEYTRUDA, work. And as I just mentioned, KEYTRUDA works in many other cancers, so it has the potential of really unlocking PCV working in other cancers. But first, let’s see what the data shows. I won’t get ahead of our skis here.
https://seekingalpha.com/article/4518530-moderna-inc-mrna-management-presents-43rd-annual-goldman-sachs-global-healthcare-conference?utm_source=stck.pro&utm_medium=referral
Moderna to invest 500 mln euros in Spain, PM Sanchez says:
Magníficas noticias. España liderará la producción de vacunas ARNm con un nuevo laboratorio y una inversión de más de 500 M€. Hoy me he reunido con el vicepresidente de @moderna_tx Dan Staner, quien me ha expuesto los planes de expansión de la farmacéutica en nuestro país. pic.twitter.com/YpgL1gWvx6
— Pedro Sánchez (@sanchezcastejon) June 14, 2022
U.S. FDA advisers back authorization of $MRNA COVID vaccine for ages 6-17
For the first time, $MRNA could compete with Pfizer for older kids' vaccines:
https://www.bizjournals.com/boston/news/2022/06/14/moderna-childrens-vaccines-fda-adcomm.html?utm_source=sy&utm_medium=nsyp&utm_campaign=yh
big company!
imo...RRN is total complete...MRNA_________in my opinion,
Short sellers
All the big money conservatives are shorting the market together intending to make Biden look bad.
You can believe it is not true, but I know better.
WHO would not like it at these level ?
MRNA $$$$$
Goldman Sachs Likes These 2 Beaten-Down Stocks for Triple-Digit Upside:
“We expect shares to rise on an announcement of US government purchasing of new vaccines for the fall as it would show the potential for upside to MRNA’s estimated ~$21bn in Advance Purchase Agreements (APAs),” the 5-star analyst explained. “Broadly, we believe investors are underestimating the optionality of MRNA’s platform which has been significantly de-risked by the billions of vaccinations given over the past two years using mRNA technology.”
Richter, though, is anticipating a meaningful recovery; the analyst has a Buy rating for the shares backed by a $290 price target.
https://finance.yahoo.com/news/goldman-sachs-likes-2-beaten-223920027.html
Yep. It's ugly out there. All markets taking a big hit. Just makes me wonder where the heck all the money went.
Looks like every company in the S&P is junk. LOL
MRNA Junk company. Scam pump and dump government garbage. Don't trust any word they say. All sheep talk.
Yes, that’s MRNA $$$$$
FDA says Moderna's COVID vaccine is safe and effective for children:
https://www.fda.gov/media/159189/download
https://www.axios.com/2022/06/11/fda-moderna-covid-vaccine-safe-effective-children
imo..
see you soon my friend!
$MRNA
Very nice Axel
Going to Germany a few days , family visit !
Have a great weekend you and all !
MRNA $$$$$
Long and more strong !
Winner in 2022 and 2023 ……….!
MRNA $$$$$
Breaking Barriers – the First Patient in the World Receives Moderna mRNA Trial Infusion for Glycogen Storage Disease at UConn Health
It is hoped that the investigational mRNA treatment will provide the missing code to permit the liver to make the defective protein of GSD-Ia.
https://today.uconn.edu/2022/06/breaking-barriers-the-first-patient-in-the-world-receives-moderna-mrna-trial-infusion-for-glycogen-storage-disease-at-uconn-health/
ARKG is an actively managed Exchange Traded Fund (ETF) established a new position in MRNA today with 173k shares.
We are going to be on an upward trajectory as more news comes out this month, institutions/hedge funds will start to pile in!
Unbelievable Bro
Moderna will be chosen as the vaccine for the fall booster!
Boosters alone will maintain $20b revenue levels as pipeline commercializes in the next few years
huge news: MODERNA ANNOUNCES OMICRON-CONTAINING BIVALENT BOOSTER CANDIDATE MRNA-1273.214 DEMONSTRATES SUPERIOR ANTIBODY RESPONSE AGAINST OMICRON
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx
A seasoned investor will know not to always follow a chart when there are many things in the pipeline!!
CEO Stéphane Bancel's: https://mastersofscale.com/bancel2/
In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Moderna (MRNA – Research Report), with a price target of $506.00
https://www.tipranks.com/news/blurbs/moderna-mrna-gets-a-buy-rating-from-brookline-capital-markets?utm_source=advfn.com&utm_medium=referral
Very nice !
Thank you !
MRNA $$$$$
MODERNA ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 3 STUDY OF SEASONAL INFLUENZA VACCINE CANDIDATE (MRNA-1010)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-3-Study-of-Seasonal-Influenza-Vaccine-Candidate-mRNA-1010/default.aspx
I am not expecting something different Bro
Only up from now !
MRNA $$$$$
Is the Options Market Predicting a Spike in Moderna Stock....
https://finance.yahoo.com/news/options-market-predicting-spike-moderna-191207634.html
anything could happen!!!!!!!!
“This report warns that without global co-operation moving forward, the COVID-19 pandemic situation will likely continue until at least 2027. Within the report, three possible scenarios are outlined moving through to 2027 are based upon the advancement and development of the SARS-CoV-2 virus, and the extent and effectiveness of COVID-19 vaccines globally.
https://www.sciencemediacentre.co.nz/2022/05/17/forecasting-the-next-five-years-of-the-covid-19-crisis-expert-reaction/
The White House expects vaccinations of young children to begin in earnest as early as June 21, if federal authorities approve their use in coming weeks, White House COVID response coordinator Ashish Jha said on Thursday.
Moderna in March released trial data that showed a two-dose formulation of its vaccine was safe and generated a similar immune response in young children as in adults.
The FDA's independent advisers will discuss the two applications in a meeting set for June 14-15!
$MRNA
You said “Wuhan strikes again”
That reveals your confirmation bias.
Followers
|
176
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
13326
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |